FIELD: pharmaceuticals.
SUBSTANCE: group of inventions refers to preparations for oral administration of an inhibitor of PDE V avanafil. Tablet disintegrating in the mouth includes a therapeutically effective amount of avanafil, an absorption-enhancing composition containing a surfactant, which is sucrose palmitate, a composition disintegrating in the mouth, comprising a disintegrant, a lubricant and a porous component in a pharmaceutically acceptable carrier. Also disclosed is a method of administering a PDE V inhibitor to a subject and a method of producing a disintegrating tablet.
EFFECT: group of inventions provides higher absorption of the active agent.
13 cl, 4 dwg, 1 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SOLID DOSED OUT FORMS INCLUDING FIBRAT AND STATIN | 2004 |
|
RU2343905C2 |
| LONG-CHAIN LIPOSBALANCED ESTERS OF TESTOSTERONE FOR ORAL DELIVERY | 2014 |
|
RU2722592C2 |
| PREPARATION OF GLUCOKINASE ACTIVATOR FOR ORAL ADMINISTRATION AND METHOD FOR PREPARATION THEREOF | 2017 |
|
RU2728824C1 |
| APPLICATION OF ZOLEDRONE ACID, ITS SALTS, HYDRATES AND METHOD OF ANTINOCICEPTIVE OR ANTIALLODYNIC TREATMENT OF PAIN, METHOD OF NEUROTIC PAIN TREATMENT | 2001 |
|
RU2325913C2 |
| SOLID PER ORAL MEDICATION, CONTAINING INTENSIFIER | 2007 |
|
RU2437662C2 |
| PHARMACEUTICAL BIPHOSPHONATE APPLICATION | 2002 |
|
RU2297229C2 |
| RASAGILINE COMPOSITIONS WITH PROLONGED RELEASE AND USE THEREOF | 2011 |
|
RU2734632C2 |
| DOSAGE FORMS OF RISEDRONATE | 2005 |
|
RU2381791C2 |
| RASAGILINE COMPOSITIONS OF PROLONGED RELEASE AND USE THEREOF | 2011 |
|
RU2607595C2 |
| TRANSMUCOSAL SYSTEM OF DELIVERY OF MEDICAL PRODUCTS | 2004 |
|
RU2342953C2 |
